A Deep Dive On Early Time-to-Toci

Join Dr. Rahul Banerjee, Advanced Fellow of BMT / CAR T Therapy in the Department of Medicine at the University of California San Francisco, and Dr. Nina Shah, Associate Professor in the Department of Medicine at UC San Francisco, as they discuss their paper “Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.” The paper was co-authored by Drs. Shah and Banerjee, along with several colleagues, and was published in ASTCT’s Transplantation and Cellular Therapy Journal in March.

Tags: astct, myeloma, BMT, CART, antigen, T cell, Chimeric antigen receptor